4MO Final overall survival (OS) data of sintilimab plus pemetrexed (SPP) and platinum as first-line (1L) treatment for locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase III ORIENT-11 study

Y Yang,Z Wang,J Fang,Q Yu,B Han,S Cang,G Chen,X Mei,Z Yang,V Stefaniak,Y Lin,S Wang,W Zhang,L Sun,Y Zhang

doi:10.1016/j.annonc.2022.02.013

4MO Final overall survival (OS) data of sintilimab plus pemetrexed (SPP) and platinum as first-line (1L) treatment for locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase III ORIENT-11 study

Y Yang, Z Wang + Show 13 more

Open Access

https://doi.org/10.1016/j.annonc.2022.02.013

Copy DOI

Journal: Annals of Oncology	Publication Date: Apr 1, 2022
Citations: 6	License type: elsevier-specific: oa user license

Affiliation: Zhengzhou University, Eli Lilly (United States), Guangdong Medical College, Sun Yat-sen University Cancer Center, Peking University Cancer Hospital, Shanghai Jiao Tong University, Tumor Hospital of Guangxi Medical University, Anhui Provincial Hospital, Shandong Tumor Hospital, Shandong First Medical University, Third Affiliated Hospital of Harbin Medical University

#Metastatic Nonsquamous NSCLC #Overall Survival + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

In ORIENT-11, 1L SPP significantly improved progression-free survival (PFS) compared with placebo plus pemetrexed-platinum (PPP) in patients (pts) with AMnsqNSCLC. The study met the primary endpoint of PFS at interim analysis (15NOV2019). Updated OS analysis showed OS benefit. Here we report final OS from ORIENT-11 (Clinical Trials.gov: NCT03607539) using a September 15, 2021 data cutoff.

Full Text